BioVie (BIVI) 10-Q 12 May 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2023	May 05, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	001-39015
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Entity Tax Identification Number	46-2510769
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	680 W Nye Lane Suite 204
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89703
City Area Code	775
Local Phone Number	888-3162
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	BIVI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		36,280,541

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 31,276,197	$ 18,641,716
Investments in U.S. Treasury Bills	12,521,448
Prepaids and other assets	249,790	137,879
Total current assets	44,047,435	18,779,595
Operating lease right-of-use assets	90,549	118,254
Intangible assets, net	694,439	866,472
Goodwill	345,711	345,711
Other assets, non-current	4,562	4,562
TOTAL ASSETS	45,182,696	20,114,594
CURRENT LIABILITIES:
Accounts payable and accrued expenses	4,839,209	2,442,804
Current portion of other liabilities	193,542	1,304,925
Current portion of operating lease liabilities	43,314	38,884
Current portion of Note payable, net of financing cost, unearned premium and discount of $1,108,932 at March 31, 2023	6,391,068
Warrant liabilities	1,956,781	194,531
Embedded derivative liability	2,580,425	188,030
Total current liabilities	16,004,339	4,169,174
Other liabilities, net of current portion		48,385
Operating lease liabilities, net of current portion	54,465	87,414
Note payable, net of current portion, financing cost, unearned premium and discount of $94,368 at March 31, 2023 and $2,861,314 at June 30, 2022	7,405,632	12,138,686
TOTAL LIABILITIES	23,464,436	16,443,659
STOCKHOLDERS’ EQUITY :
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2023 and June 30, 2022, respectively; 36,153,911 shares issued of which 36,131,311 shares outstanding at March 31, 2023 and 24,984,083 issued and outstanding at June 30, 2022;	3,613	2,496
Additional paid in capital	313,811,910	254,638,329
Accumulated other comprehensive income	16,505
Accumulated deficit	(292,113,766)	(250,969,890)
Treasury Stock	(2)
Total stockholders’ equity	21,718,260	3,670,935
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 45,182,696	$ 20,114,594

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Statement of Financial Position [Abstract]
Unearned premium and discount current	$ 1,108,932
Unearned premium and discount	$ 94,368	$ 2,861,314
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares Issued	36,153,911	24,984,083
Common Stock, Shares Outstanding	36,131,311	24,984,083

Condensed Statements of Operati

Condensed Statements of Operations and other comprehensive income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
OPERATING EXPENSES:
Amortization	$ 57,344	$ 57,344	$ 172,033	$ 172,032
Research and development expenses	11,196,835	3,577,142	24,999,665	11,385,586
Selling, general and administrative expenses	2,520,330	2,114,348	8,931,957	6,403,508
TOTAL OPERATING EXPENSES	13,774,509	5,748,834	34,103,655	17,961,126
LOSS FROM OPERATIONS	(13,774,509)	(5,748,834)	(34,103,655)	(17,961,126)
OTHER EXPENSE (INCOME):
Change in fair value of derivative liabilities	366,093	386,450	4,154,645	(1,168,804)
Interest expense	1,082,762	918,633	3,192,631	1,236,010
Interest income	(182,201)	(13,273)	(307,055)	(32,621)
TOTAL OTHER EXPENSE, NET	1,266,654	1,291,810	7,040,221	34,585
NET LOSS	(15,041,163)	(7,040,644)	(41,143,876)	(17,995,711)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (15,041,163)	$ (7,040,644)	$ (41,143,876)	$ (17,995,711)
NET LOSS PER COMMON SHARE
- Basic	$ (0.43)	$ (0.28)	$ (1.32)	$ (0.73)
- Diluted	$ (0.43)	$ (0.28)	$ (1.32)	$ (0.73)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
- Basic	35,325,580	24,984,083	31,217,382	24,555,382
- Diluted	35,325,580	24,984,083	31,217,382	24,555,382
NET LOSS	$ 15,041,163	$ 7,040,644	$ 41,143,876	$ 17,995,711
Other comprehensive income
Unrealized gain on investments for available-for-sale	16,505		16,505
Other comprehensive income	16,505		16,505
Comprehensive loss	$ (15,024,658)	$ (7,040,644)	$ (41,127,371)	$ (17,995,711)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (41,143,876)	$ (17,995,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets	172,033	172,032
Stock based compensation - restricted stock units	1,589,526	384,454
Stock based compensation expense - stock options	3,480,425	4,004,718
Amortization of financing costs	127,664	56,740
Accretion of unearned loan discount	1,201,083	533,815
Accretion of loan premium	329,267	94,444
Change in operating lease right-of-use assets	27,705	(77)
Change in fair value of derivative liabilities	4,154,645	(1,168,804)
Change in operating assets and liabilities
Prepaids and other assets	(111,911)	(191,480)
Accounts payable and accrued expenses	2,396,405	209,949
Operating lease liabilities	(28,519)
Other liabilities	(1,159,768)	774,167
Net cash used in operating activities	(28,965,321)	(13,125,753)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of U.S. Treasury Bills	(12,504,943)
Net cash used in investing activities	(12,504,943)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	48,196,665	18,511,009
Proceeds from note payable net of financing costs		14,609,915
Proceeds from exercise of stock options	2,240
Net proceeds from issuance of common stock - Related Party	5,905,840
Net cash provided by financing activities	54,104,745	33,120,924
Net increase in cash and cash equivalents	12,634,481	19,995,171
Cash and cash equivalents, beginning of period	18,641,716	4,511,642
Cash and cash equivalents, end of period	31,276,197	24,506,813
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	62,693	551,011
SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Right of use assets obtained in exchange for lease obligations		130,039
Unrealized gain on U.S. Treasury Bills	$ 16,505

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stocks [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 2,232	$ 229,933,505			$ (224,885,422)	$ 5,050,315
Beginning balance, shares at Jun. 30, 2021	22,333,324
Treasury Stock, Beginning balance, shares at Jun. 30, 2021
Proceeds from issuance of common stock, net of costs of $338,846	$ 259	18,510,750				18,511,009
Proceeds from issuance of common stock, shares	2,592,000
Stock-based compensation – restricted stock units	$ 3	286,756				286,759
Stock-based compensation - restricted stock units, Shares	37,049
Stock option based compensation		1,926,962				1,926,962
Net loss					(5,540,753)	(5,540,753)
Ending balance, value at Sep. 30, 2021	$ 2,494	250,657,973			(230,426,175)	20,234,292
Ending balance, shares at Sep. 30, 2021	24,962,373
Treasury Stock, Ending balance, shares at Sep. 30, 2021
Stock-based compensation – restricted stock units	$ 2	97,693				97,695
Stock-based compensation - restricted stock units, Shares	21,710
Stock option based compensation		1,147,422				1,147,422
Net loss					(5,414,317)	(5,414,317)
Ending balance, value at Dec. 31, 2021	$ 2,496	251,903,088			(235,840,492)	16,065,092
Ending balance, shares at Dec. 31, 2021	24,984,083
Stock option based compensation		930,334				930,334
Net loss					(7,040,644)	(7,040,644)
Ending balance, value at Mar. 31, 2022	$ 2,496	252,833,422			(242,881,133)	9,954,785
Ending balance, shares at Mar. 31, 2022	24,984,083
Treasury Stock, Ending balance, shares at Mar. 31, 2022
Beginning balance, value at Jun. 30, 2022	$ 2,496	254,638,329			(250,969,890)	3,670,935
Beginning balance, shares at Jun. 30, 2022	24,984,083
Treasury Stock, Beginning balance, shares at Jun. 30, 2022
Proceeds from issuance of common stock, net of costs of $338,846	$ 155	5,903,527				5,903,682
Proceeds from issuance of common stock, shares	1,544,872
Stock-based compensation – restricted stock units		17,537				17,537
Stock option based compensation		878,640				878,640
Net loss					(10,415,711)	(10,415,711)
Proceeds from issuance of common stock, net of costs of $94,160 – Related Party	$ 364	5,905,476				5,905,840
Proceeds from issuance of common stock related party, shares	3,636,364
Ending balance, value at Sep. 30, 2022	$ 3,015	267,343,509			(261,385,601)	5,960,923
Ending balance, shares at Sep. 30, 2022	30,165,319
Treasury Stock, Ending balance, shares at Sep. 30, 2022
Proceeds from issuance of common stock, net of costs of $338,846	$ 431	32,524,230				32,524,661
Proceeds from issuance of common stock, shares	4,312,741
Stock-based compensation – restricted stock units		1,554,453				1,554,453
Stock option based compensation		1,712,787				1,712,787
Cashless exercise of options	$ 3	(3)
Cashless exercise of options, shares	21,882
Cashless exercise of warrants
Cashless exercise of warrants, shares	3,590
Proceeds from exercise of options		2,240				2,240
Proceeds from exercise of options, shares	800
Net loss					(15,687,002)	(15,687,002)
Ending balance, value at Dec. 31, 2022	$ 3,449	303,137,216			(277,072,603)	26,068,062
Ending balance, shares at Dec. 31, 2022	34,504,332
Treasury Stock, Ending balance, shares at Dec. 31, 2022
Proceeds from issuance of common stock, net of costs of $338,846	$ 151	9,768,171				9,768,322
Proceeds from issuance of common stock, shares	1,515,078
Stock-based compensation – restricted stock units		17,536				17,536
Issuance of restricted stock units	$ 13	(11)	$ (2)
Issuance of restricted stock units, shares	134,501		(22,800)
Stock option based compensation		888,998				888,998
Net loss					(15,041,163)	(15,041,163)
Unrealized gain on available-for-sale securities				16,505		16,505
Ending balance, value at Mar. 31, 2023	$ 3,613	$ 313,811,910	$ (2)	$ 16,505	$ (292,113,766)	$ 21,718,260
Ending balance, shares at Mar. 31, 2023	36,153,911
Treasury Stock, Ending balance, shares at Mar. 31, 2023			(22,800)

Background Information

Background Information	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background Information	1. Background Information BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), a privately held clinical-stage pharmaceutical company, in June 2021 (See Note 5 Related Party Transactions ). The Phase 2 study of NE3107 in Parkinson’s disease (“PD” (NCT05083260), completed in December was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. 45 patients with a defined L-dopa “off state” were randomized 1:1 to placebo:NE3107 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objectives are safety and a drug-drug interaction study as requested by the FDA to demonstrate the absence of adverse interactions of NE3107 with levodopa; and 2) the secondary objective is to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity can be seen in humans. Both objectives were met. The Company continues to process its findings from its completed NM201 study as it prepares for the next round of clinical studies in PD. Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and Amyotrophic lateral sclerosis (ALS). NE3107 is an oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea. The Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis was paused in March 2023. Data from the first 15 patients treated with BIV201 plus standard of care (SOC) resulted in a 34% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment (p=0.0046). This improvement was significantly different from those treated with SOC only who experienced a mean increase in ascites fluid of 3.1% (BIV201 vs. SOC p=0.05). Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid (p=0.001), which was significantly different from those treated with SOC (p=0.007). This improvement was sustained in this group during the 3 months after treatment initiation as compared to the 3-month pre-treatment period (43% reduction, p=0.06). Overall treatment appeared to be well tolerated. There were no unexpected serious adverse events and overall safety was consistent with the patient population. The current trial (NCT04112199) evaluates the efficacy of BIV201 combined with SOC, compared to SOC alone, for the treatment of refractory ascites. Terlipressin was administered with a continuous low dose infusion via a portable pump in two 28-day treatment cycles. The primary endpoints are the incidence of complications of at least Grade 2 severity, and the change in cumulative ascites in the 12-week period following randomization compared to a 12-week pre-treatment period. The BIV201 trial planned to enroll 30 patients to be treated in the home care setting. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. The BIV201 development program was initiated by LAT Pharma LLC (“LAT Pharma”). On April 11, 2016, the Company acquired LAT Pharma and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin), if approved, to be shared by the members of LAT Pharma, PharmaIn Corporation and The Barrett Edge, Inc

Liquidity

Liquidity	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	2. Liquidity The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company’s ability to raise capital to support its operations. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company had working capital of $ 28 43.8 21.7 292 Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The duration and spread of the COVID-19 pandemic and the long-term impact of COVID-19 and any variants on the financial markets and the overall economy continue to be uncertain and cannot be predicted at this time. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected. Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2022 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2022 and 2021 in our Annual Report on Form 10-K filed with the SEC on September 27, 2022. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed with the SEC on September 27, 2022 (the “2022 Form 10-K”). Net loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of Class A common stock, par value $ 0.0001 The table below shows the number of outstanding stock options, warrants and restricted stock units as of March 31, 2023 and 2022: Schedule of Dilutive securities were excluded from the computation of diluted loss per share March 31, 2023 March 31, 2022 Number of Shares Number of Shares Stock Options 3,443,997 2,438,044 Warrants 7,770,285 511,463 Restricted Stock Units 527,549 - Total 11,741,831 2,949,507 Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations since the 2022 Form 10-K. Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of 3 months or less. Adverse Developments Affecting the Financial Services Industry and Concentration of Risk As of March 31, 2023 and December 31, 2022, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations. Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than 3 months, are accounted for as available for sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying the statements of operations and other comprehensive income. Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions.

Investments in U.S. Treasury Bi

Investments in U.S. Treasury Bills available for sale	9 Months Ended
	Mar. 31, 2023
Investments In U.s. Treasury Bills Available For Sale
Investments in U.S. Treasury Bills available for sale	4. Investments in U.S. Treasury Bills available for sale The following is a summary of the U.S. Treasury Bills held at March 31, 2023: Schedule of U.S. treasury bills held Total Accumulated Amortized Gross Gross Fair Value Other Comprehensive Income U.S. Treasury Bills due is 3 - 6 months $ 12,504,943 $ 16,505 $ - $ 12,521,448 $ 16,505

Intangible Assets

Intangible Assets	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5 . Intangible Assets The Company’s intangible assets consist of intellectual property acquired from LAT Pharma. and are amortized over their estimated useful lives. The following is a summary of the Company’s intangible assets as of March 31, 2023 and June 30, 2022: Schedule of intangible assets March 31, 2023 June 30, 2022 Intellectual Property $ 2,293,770 $ 2,293,770 Less Accumulated Amortization (1,599,331 ) (1,427,298 ) Intellectual Property, Net $ 694,439 $ 866,472 Amortization expense was $ 57,344 172,033 172,032 10 Estimated future amortization expense is as follows: Schedule of future amortization expense Year ending June 30, 2023 (Remaining three months) $ 57,344 2024 229,377 2025 229,377 2026 178,341 Intellectual Property, Net $ 694,439

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions Equity Transactions with Acuitas On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (Acuitas), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 3,636,364 Asset Acquisition with NeurMedix On April 27, 2021, the Company entered into an Asset Purchase Agreement (“APA”) with NeurMedix and Acuitas, which are related party affiliates, pursuant to which the Company acquired certain assets from NeurMedix and assumed certain liabilities of NeurMedix,. The acquired assets include, among others, certain assets related to the drug candidates then being developed by NeurMedix, including NE3107. On June 10, 2021, and pursuant to the terms of the APA, the Company issued to Acuitas (as NeurMedix’s assignee) 8,361,308 shares of the Company’s common stock and made a cash payment to Acuitas of approximately $2.3 million. Since the transaction was between entities under common control, there were no fair value adjustments of the purchased assets, and the historical cost basis of the purchased assets was zero. The total consideration paid was expensed as in process research and development expense in the year ended June 30, 2021. Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of the Company’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 89.9999% of the Company’s issued and outstanding common stock. Subject to the terms and conditions of the APA, as amended, the Company may now be obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of up to 18 million shares of the Company’s common stock, with 4.5 million shares issuable upon the achievement of each of the four milestones set forth in the APA, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of the Company’s issued and outstanding common stock.

Other Liabilities

Other Liabilities	9 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities	7. Other Liabilities The current portion of other liabilities at March 31, 2023 and June 30, 2022 were $ 193,542 1.3 193,542 580,614 1,161,000

Notes Payable

Notes Payable	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	8. Notes Payable On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan provided for an additional $5 million to be available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.00 8.0 The Loan Agreement requires monthly interest-only payments during the first eighteen months of the term of the Loan. Following the interest-only period, the Company will make equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and Tranche 2. The Loan Agreement includes a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s common stock at a conversion price of $6.98 per share. On the Closing Date, the Company issued to Avenue warrants to purchase 361,002 shares of common stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $5.82. The Avenue Warrants are exercisable until November 30, 2026. The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes; approximately $ 1.4 2.2 3.7 390,000 850,000 1.1 547,000 43,000 400,000 3.2 1.5 1.2 329,000 The carrying value of notes payable at March 31, 2022 was approximately $ 11.6 3.1 333,000 94,000 919,000 1.2 43,000 57,000 71,000 94,000 As of March 31, 2023, the remaining principal balance of $15 million under the Loan is payable in 18 monthly equal installments beginning July 1, 2023; for a total of $10.0 million and $5.0 million in the fiscal years ended June 30, 2024 and 2025 respectively. The following is a summary of the Notes Payable as of March 31, 2023 and June 30, 2022: Current portion of Notes Payable Schedule of note payable March 31, 2023 June 30, 2022 Current portion of Notes Payable $ 7,500,000 $ - Less debt financing costs (134,757 ) - Less unearned discount (1,267,811 ) - Plus accretion of loan premium 293,636 - Current portion of Notes Payable, net of financing costs, unearned premiums and discount $ 6,391,068 $ - Non-current portion of Notes Payable March 31, 2023 June 30, 2022 Notes Payable $ 7,500,000 $ 15,000,000 Less debt financing costs (28,369 ) (290,790 ) Less unearned discount (266,908 ) (2,735,802 ) Plus accretion of loan premium 200,909 165,278 Notes Payable, net of the current portion, financing costs, unearned premiums and discount $ 7,405,632 $ 12,138,686 Estimated future amortization expense and accretion of premium is as follows: Schedule of Estimated future amortization expense and accretion of premium Unearned Discount Debt Financing Costs Loan accretion Premium Year ending June 30, 2023 (Remaining 3 months) $ 400,362 $ 42,555 $ 92,727 2024 1,023,145 108,751 236,970 2025 111,212 11,820 25,758 Total $ 1,534,719 $ 163,126 $ 355,455

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements At March 31, 2023 and June 30, 2022, the estimated fair value of derivative liabilities measured on a recurring basis are as follows: Schedule of derivative liabilities at fair value Fair Value Measurements at March 31, 2023 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 1,956,781 $ 1,956,781 Derivative liability - Conversion option on notes payable - - 2,580,425 2,580,425 Total derivatives $ - $ - $ 4,537,206 $ 4,537,206 Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 194,531 $ 194,531 Derivative liability - Conversion option on note payable - - 188,030 188,030 Total derivatives $ - $ - $ 382,561 $ 382,561 The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2023: Fair value, liabilities measured on recurring basis Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2022 $ 194,531 $ 188,030 Additions to level 3 liabilities - - Change in in fair value of level 3 liability 1,762,250 2,392,395 Transfer in and/or out of Level 3 - - Balance at March 31, 2023 $ 1,956,781 $ 2,580,425 The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2022: Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2021 $ - $ - Additions to level 3 liabilities 1,456,512 2,213,466 Change in fair value of level 3 liability (433,218 ) (735,586 ) Transfer in and/or out of Level 3 - - Balance at March 31, 2022 $ 1,023,294 $ 1,477,880 The fair values of derivative liabilities for the Avenue Warrants and conversion option at March 31, 2023 in the accompanying balance sheet, were approximately $2.0 million and approximately $2.6 million, respectively. The total change in the fair value of the derivative liabilities totaled approximately $366,000 and $4.2 million for the three and nine months ended March 31, 2023, respectively; and accordingly, was recorded in the accompanying statement of operations. The assumptions used in the Black Scholes model to value the derivative liabilities at March 31, 2023 included the closing stock price of $ 8.08 5.82 3.7 3.7 83.7 6.98 1.7 4.35 76.24 Derivative liability – Avenue Warrants The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet and anti-dilution provisions or adjustments to the strike price due to an occurrence of a future event are accounted for as derivative financial instruments. The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompany balance sheet at March 31, 2023. The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at their fair values at the date of issuance and remeasured at March 31, 2023. The assumptions used for the fair value calculation at November 30, 2021 included: the closing stock price of $ 6.44 5.82 5 1.14 74.4 Embedded derivative liability – Conversion Option The embedded derivative liability represents the optional conversion feature of up to $5.0 million of the outstanding Loan, which meets the definition of a derivative and requires bifurcation from the loan amount. The Black Scholes model was used to calculate the fair value of the embedded derivative to bifurcate the embedded derivative amount representing the conversion option from the Loan amount funded. The assumption used for the fair value calculation at November 30, 2021 included: the closing stock price of $ 6.44 6.98 3 0.81 76.85 Financial assets As of March 31, 2023, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories. Measured at fair value on a recurring basis Fair Value Measurements at March 31, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalent $ 13,098,912 $ - $ - $ 13,098,912 U.S. Treasury Bills due in 3 months or less 18,177,285 - - 18,177,285 U.S. Treasury Bills due in 3 - 6 months 12,521,448 - - 12,521,448 Total $ 43,797,645 $ - $ - $ 43,797,645 Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalent $ 18,641,716 $ - $ - $ 18,641,716 U.S. Treasury Bills due in 3 months or less - - - - U.S. Treasury Bills due in 3 - 6 months - - - - Total $ 18,641,716 $ - $ - $ 18,641,716

Equity Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Equity Transactions	10. Equity Transactions Stock Options The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2023: Schedule of summarizes the activity relating to the Company’s stock options Options Weighed-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2022 3,398,764 7.42 6.8 - Granted 205,000 6.08 5.2 347,350 Options Expired (10,000 ) 28.69 - - Options Canceled (49,667 ) 7.74 - - Options Exercised (100,100 ) 7.79 - - Outstanding at March 31, 2023 3,443,997 $ 7.29 6.0 $ 6,474,701 Exercisable at March 31, 2023 1,135,948 $ 8.60 5.8 $ 1,427,537 The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following weighted-average assumptions for the nine months ended March 31, 2023 and 2022: Schedule of assumptions used March 31, 2023 March 31, 2022 Expected life of options (In years) 5 5 Expected volatility 79.52 75.12 Risk free interest rate 3.61 1.60 Dividend Yield 0 0 Expected volatility is based on the historical volatilities of the daily closing price of the common stock of three comparable companies and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred. The total stock option-based compensation expense for three-month ended March 31, 2023 and 2022 was of $ 888,998 930,334 3,480,425 4,004,718 The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2023: Schedule of summary of stock options outstanding and exercisable Exercise Price Outstanding Weighted Average Contract Life Exercisable $ 1.69 124,520 4.3 - $ 1.81 10,000 4.2 - $ 1.98 72,000 4.2 2,000 $ 2.74 124,167 8.9 28,972 $ 2.80 5,600 1.9 5,600 $ 3.20 248,167 8.9 73,634 $ 3.24 25,000 8.9 5,417 $ 3.75 4,800 0.9 4,800 $ 5.04 755,000 4.4 188,750 $ 5.21 10,000 9.7 - $ 6.12 195,000 4.7 48,750 $ 6.25 1,600 0.6 1,600 $ 7.50 800 1.6 800 $ 7.74 1,241,668 8.4 447,000 $ 8.75 1,600 0.8 1,600 $ 9.54 800 2.6 800 $ 9.90 800 2.6 800 $ 13.91 618,475 2.8 321,425 $ 42.09 4,000 2.9 4,000 3,443,997 1,135,948 Issuance of common stock for cash During the three months ended September 30, 2021, the Company issued 2,592,000 8.00 18.5 2.2 On September 24, 2021, the Company issued 92,000 of its Class A common stock at $ 8.00 707,000 29,000 On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the three months ended March 31, 2023, the Company sold 1,515,078 9.8 3 339,000 7,372,691 48.2 3 1.9 Issuance of common stock through exercise of stock options and warrants During the three months ended December 31, 2022, the Company issued 21,882 99,300 7.64 In November 2022, the Company issued 800 800 2.80 In October, the Company issued 3,590 8,000 2.25 Issuance of restricted stock units for services On August 20, 2021, the Company awarded 58,759 7.74 58,759 384,456 On June 21, 2022, the Company awarded 124,520 1.69 17,536 52,610 On November 23, 2022, the Company awarded 506,496 6.12 584,424 72,612 25 22,800 On November 23, 2022, the Company issued equity awards for the board of directors’ annual compensation. Four directors received RSUs to purchase a total of 155,636 6.12 952,492 195,000 6.12 791,700 1,744,192 39,089 Issuance of Stock Options On August 20, 2021, the Company granted, under the 2019 Omnibus Plan, stock options to purchase 1,365,835 5 7.74 On February 1, 2022, the Company granted stock options to purchase 124,167 shares of common stock to a new employee. Twenty percent ( 20 80 5 3.20 During the three months ended March 31, 2022, the Company granted, stock options to purchase shares of common stock totaling 273,167 to four new employees. Pursuant to a former employee Separation Agreement, dated April 11, 2022, the Company modified a former employee’s stock option award granted on August 20, 2021, pursuant to the 2019 Omnibus Plan (“2021 Options Grant”). Pursuant to the terms of the Separation Agreement, effective on July 8, 2022 (“the Separation Date”), the Company accelerated the vesting of options scheduled to vest on the first and second anniversary of the grant date as deemed vested (“Accelerated Options”) and after giving effect to the Accelerated Options, extended the exercise period of the total vested outstanding and unexercised options (totaling 74,500 options) to one year following the Separation Date. The unvested portion of the 2021 Option Grant (totaling 49,667 options) was canceled. The modification was remeasured as of July 8, 2022, and the incremental difference totaled $181,154, net credit, due to the original exercise price of $7.74 being greater than the stock price of $1.80 on the remeasurement date, and accordingly was recognized on July 8, 2022. On December 6, 2022, stock options to purchase 10,000 48 5.21 On April 4, 2023, stock options to purchase 124,167 20 80 Stock Warrants The following table summarizes warrant activity during the nine months ended March 31, 2023: Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2022 510,372 $ 6.17 3.8 $ - Granted 7,272,728 1.82 4.9 - Expired (4,815 ) 75.00 - - Exercised (8,000 ) 2.25 - - Outstanding and exercisable at March 31, 2023 7,770,285 $ 2.06 4.3 $ 46,935,207 Of the above warrants, 101,380 expire in the fiscal year ending June 30, 2025, 35,175 expire in the fiscal year ending June 30, 2026, and 7,633,730 expire in the fiscal year ending June 30, 2027.

Leases

Leases	9 Months Ended
	Mar. 31, 2023
Leases
Leases	11. Leases Office Lease The Company paid an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 897603. The rental agreement is for a one-year term. On February 26, 2022, the Company’s San Diego office relocated to 5090 Shoreham Place, San Diego, CA 92122. The term for the new office lease is 38 months and commenced on March 1, 2022. The monthly base rate of $4,175 begins June 1, 2022, with annual increases of three percent. The operating lease costs recognized in our statement of operations were approximately $ 13,000 23,000 36,900 76,500 The following table provides balance sheet information related to leases as of March 31, 2023 and June 30, 2022: Schedule of balance sheet information related to leases March 31, 2023 June 30, 2022 Assets Operating lease, right-of-use asset, net $ 90,549 $ 118,254 Liabilities Current portion of operating lease liabilities $ 43,314 $ 38,884 Operating lease liabilities, net of current portion 54,465 87,414 Total operating lease liabilities $ 97,779 $ 126,298 At March 31, 2023, the future estimated minimum lease payments under non-cancelable operating leases are as follows: Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2023 (Remaining 3 months) $ 12,900 2024 52,156 2025 44,636 Total minimum lease payments 109,692 Less amount representing interest (11,913 ) Present value of future minimum lease payments 97,779 Less current portion of operating lease liabilities (43,314 ) Operating lease liabilities, net of current portion $ 54,465 Total cash paid for amounts included in the measurement of lease liabilities were $ 12,650 37,700 The weighted average remaining lease term and discount rate as of March 31, 2023 and June 30, 2022 were as follows: Schedule of weighted average remaining lease term and discount rate March 31, 2023 June 30, 2022 Weighted average remaining lease term (Years) Operating leases 2.0 2.8 Weighted average discount rate Operating leases 10.75 % 10.75 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Royalty Agreements Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year.

Employee Benefit Plan

Employee Benefit Plan	9 Months Ended
	Mar. 31, 2023
Employee Benefit Plan
Employee Benefit Plan	13. Employee Benefit Plan On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”). Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan., The Company made contributions of approximately $ 16,000 28,700 80,100 75,100

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Subsequent to March 31, 2023 the Company sold 162,767 1.3 million 40,000

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation – Interim Financial Information	Basis of Presentation – Interim Financial Information These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2022 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2022 and 2021 in our Annual Report on Form 10-K filed with the SEC on September 27, 2022. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed with the SEC on September 27, 2022 (the “2022 Form 10-K”).
Net loss per Common Share	Net loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of Class A common stock, par value $ 0.0001 The table below shows the number of outstanding stock options, warrants and restricted stock units as of March 31, 2023 and 2022: Schedule of Dilutive securities were excluded from the computation of diluted loss per share March 31, 2023 March 31, 2022 Number of Shares Number of Shares Stock Options 3,443,997 2,438,044 Warrants 7,770,285 511,463 Restricted Stock Units 527,549 - Total 11,741,831 2,949,507
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations since the 2022 Form 10-K.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of 3 months or less.
Adverse Developments Affecting the Financial Services Industry and Concentration of Risk	Adverse Developments Affecting the Financial Services Industry and Concentration of Risk As of March 31, 2023 and December 31, 2022, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.
Investments in U.S. Treasury Bills	Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than 3 months, are accounted for as available for sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying the statements of operations and other comprehensive income.
Fair value measurement of assets and liabilities	Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Dilutive securities were excluded from the computation of diluted loss per share	Schedule of Dilutive securities were excluded from the computation of diluted loss per share March 31, 2023 March 31, 2022 Number of Shares Number of Shares Stock Options 3,443,997 2,438,044 Warrants 7,770,285 511,463 Restricted Stock Units 527,549 - Total 11,741,831 2,949,507

Investments in U.S. Treasury _2

Investments in U.S. Treasury Bills available for sale (Tables)	9 Months Ended
	Mar. 31, 2023
Investments In U.s. Treasury Bills Available For Sale
Schedule of U.S. treasury bills held	Schedule of U.S. treasury bills held Total Accumulated Amortized Gross Gross Fair Value Other Comprehensive Income U.S. Treasury Bills due is 3 - 6 months $ 12,504,943 $ 16,505 $ - $ 12,521,448 $ 16,505

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets March 31, 2023 June 30, 2022 Intellectual Property $ 2,293,770 $ 2,293,770 Less Accumulated Amortization (1,599,331 ) (1,427,298 ) Intellectual Property, Net $ 694,439 $ 866,472
Schedule of future amortization expense	Schedule of future amortization expense Year ending June 30, 2023 (Remaining three months) $ 57,344 2024 229,377 2025 229,377 2026 178,341 Intellectual Property, Net $ 694,439

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of note payable	Schedule of note payable March 31, 2023 June 30, 2022 Current portion of Notes Payable $ 7,500,000 $ - Less debt financing costs (134,757 ) - Less unearned discount (1,267,811 ) - Plus accretion of loan premium 293,636 - Current portion of Notes Payable, net of financing costs, unearned premiums and discount $ 6,391,068 $ - Non-current portion of Notes Payable March 31, 2023 June 30, 2022 Notes Payable $ 7,500,000 $ 15,000,000 Less debt financing costs (28,369 ) (290,790 ) Less unearned discount (266,908 ) (2,735,802 ) Plus accretion of loan premium 200,909 165,278 Notes Payable, net of the current portion, financing costs, unearned premiums and discount $ 7,405,632 $ 12,138,686
Schedule of Estimated future amortization expense and accretion of premium	Schedule of Estimated future amortization expense and accretion of premium Unearned Discount Debt Financing Costs Loan accretion Premium Year ending June 30, 2023 (Remaining 3 months) $ 400,362 $ 42,555 $ 92,727 2024 1,023,145 108,751 236,970 2025 111,212 11,820 25,758 Total $ 1,534,719 $ 163,126 $ 355,455

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of derivative liabilities at fair value	Schedule of derivative liabilities at fair value Fair Value Measurements at March 31, 2023 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 1,956,781 $ 1,956,781 Derivative liability - Conversion option on notes payable - - 2,580,425 2,580,425 Total derivatives $ - $ - $ 4,537,206 $ 4,537,206 Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 194,531 $ 194,531 Derivative liability - Conversion option on note payable - - 188,030 188,030 Total derivatives $ - $ - $ 382,561 $ 382,561
Fair value, liabilities measured on recurring basis	Fair value, liabilities measured on recurring basis Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2022 $ 194,531 $ 188,030 Additions to level 3 liabilities - - Change in in fair value of level 3 liability 1,762,250 2,392,395 Transfer in and/or out of Level 3 - - Balance at March 31, 2023 $ 1,956,781 $ 2,580,425 The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2022: Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture Balance at July 1, 2021 $ - $ - Additions to level 3 liabilities 1,456,512 2,213,466 Change in fair value of level 3 liability (433,218 ) (735,586 ) Transfer in and/or out of Level 3 - - Balance at March 31, 2022 $ 1,023,294 $ 1,477,880
Measured at fair value on a recurring basis	Measured at fair value on a recurring basis Fair Value Measurements at March 31, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalent $ 13,098,912 $ - $ - $ 13,098,912 U.S. Treasury Bills due in 3 months or less 18,177,285 - - 18,177,285 U.S. Treasury Bills due in 3 - 6 months 12,521,448 - - 12,521,448 Total $ 43,797,645 $ - $ - $ 43,797,645 Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalent $ 18,641,716 $ - $ - $ 18,641,716 U.S. Treasury Bills due in 3 months or less - - - - U.S. Treasury Bills due in 3 - 6 months - - - - Total $ 18,641,716 $ - $ - $ 18,641,716

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of summarizes the activity relating to the Company’s stock options	Schedule of summarizes the activity relating to the Company’s stock options Options Weighed-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2022 3,398,764 7.42 6.8 - Granted 205,000 6.08 5.2 347,350 Options Expired (10,000 ) 28.69 - - Options Canceled (49,667 ) 7.74 - - Options Exercised (100,100 ) 7.79 - - Outstanding at March 31, 2023 3,443,997 $ 7.29 6.0 $ 6,474,701 Exercisable at March 31, 2023 1,135,948 $ 8.60 5.8 $ 1,427,537
Schedule of assumptions used	Schedule of assumptions used March 31, 2023 March 31, 2022 Expected life of options (In years) 5 5 Expected volatility 79.52 75.12 Risk free interest rate 3.61 1.60 Dividend Yield 0 0
Schedule of summary of stock options outstanding and exercisable	Schedule of summary of stock options outstanding and exercisable Exercise Price Outstanding Weighted Average Contract Life Exercisable $ 1.69 124,520 4.3 - $ 1.81 10,000 4.2 - $ 1.98 72,000 4.2 2,000 $ 2.74 124,167 8.9 28,972 $ 2.80 5,600 1.9 5,600 $ 3.20 248,167 8.9 73,634 $ 3.24 25,000 8.9 5,417 $ 3.75 4,800 0.9 4,800 $ 5.04 755,000 4.4 188,750 $ 5.21 10,000 9.7 - $ 6.12 195,000 4.7 48,750 $ 6.25 1,600 0.6 1,600 $ 7.50 800 1.6 800 $ 7.74 1,241,668 8.4 447,000 $ 8.75 1,600 0.8 1,600 $ 9.54 800 2.6 800 $ 9.90 800 2.6 800 $ 13.91 618,475 2.8 321,425 $ 42.09 4,000 2.9 4,000 3,443,997 1,135,948
Summary of warrants activity	Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2022 510,372 $ 6.17 3.8 $ - Granted 7,272,728 1.82 4.9 - Expired (4,815 ) 75.00 - - Exercised (8,000 ) 2.25 - - Outstanding and exercisable at March 31, 2023 7,770,285 $ 2.06 4.3 $ 46,935,207

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2023
Leases
Schedule of balance sheet information related to leases	Schedule of balance sheet information related to leases March 31, 2023 June 30, 2022 Assets Operating lease, right-of-use asset, net $ 90,549 $ 118,254 Liabilities Current portion of operating lease liabilities $ 43,314 $ 38,884 Operating lease liabilities, net of current portion 54,465 87,414 Total operating lease liabilities $ 97,779 $ 126,298
Schedule of future estimated minimum lease payments under non-cancelable operating leases	Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2023 (Remaining 3 months) $ 12,900 2024 52,156 2025 44,636 Total minimum lease payments 109,692 Less amount representing interest (11,913 ) Present value of future minimum lease payments 97,779 Less current portion of operating lease liabilities (43,314 ) Operating lease liabilities, net of current portion $ 54,465
Schedule of weighted average remaining lease term and discount rate	Schedule of weighted average remaining lease term and discount rate March 31, 2023 June 30, 2022 Weighted average remaining lease term (Years) Operating leases 2.0 2.8 Weighted average discount rate Operating leases 10.75 % 10.75 %

Liquidity (Details Narrative)

Liquidity (Details Narrative)	Mar. 31, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 28,000,000
Cash and cash equivalent	43,800,000
Stockholders' equity	21,700,000
Accumulated deficit	$ 292,000,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - shares	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11,741,831	2,949,507
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,443,997	2,438,044
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,770,285	511,463
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	527,549

Significant Accounting Polici_5

Significant Accounting Policies (Details Narrative) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common Class A [Member]
Common stock, par value	$ 0.0001

Investments in U.S. Treasury _3

Investments in U.S. Treasury Bills available for sale (Details)	Mar. 31, 2023 USD ($)
Schedule of Investments [Line Items]
Total Accumulated Other Comprehensive Income	$ 16,505
US Treasury Bill Securities [Member]
Schedule of Investments [Line Items]
Amortized Cost Basis	12,504,943
Gross Unrealized Gain	16,505
Gross Unrealized loss
Fair Value	12,521,448
Total Accumulated Other Comprehensive Income	$ 16,505

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	$ 2,293,770	$ 2,293,770
Less Accumulated Amortization	(1,599,331)	(1,427,298)
Intellectual Property, Net	$ 694,439	$ 866,472

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Year ending June 30, 2023 (Remaining three months)	$ 57,344
2024	229,377
2025	229,377
2026	178,341
Intellectual Property, Net	$ 694,439	$ 866,472

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expenses	$ 57,344	$ 57,344	$ 172,033	$ 172,032
Useful Life	10 years		10 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - shares	Mar. 31, 2023	Aug. 15, 2022	Jun. 30, 2022
Related Party Transaction [Line Items]
Common Stock, shares issued	36,153,911		24,984,083
Acuitas Group Holdings L L C [Member]
Related Party Transaction [Line Items]
Common Stock, shares issued		3,636,364

Other Liabilities (Details Narr

Other Liabilities (Details Narrative) - USD ($)	Mar. 31, 2023	Jun. 30, 2022	Aug. 31, 2021
Other Liabilities Disclosure [Abstract]
Other liabilities	$ 193,542	$ 1,300,000
Accrued Bonuses, Current	$ 193,542	$ 580,614	$ 1,161,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Current portion of Notes Payable	$ 7,500,000
Less debt financing costs	(134,757)
Less unearned discount	(1,267,811)
Plus accretion of loan premium	293,636
Current portion of Notes Payable, net of financing costs, unearned premiums and discount	6,391,068
Notes Payable	7,500,000	15,000,000
Less debt financing costs	(28,369)	(290,790)
Less unearned discount	(266,908)	(2,735,802)
Plus accretion of loan premium	200,909	165,278
Notes Payable, net of the current portion, financing costs, unearned premiums and discount	$ 7,405,632	$ 12,138,686

Notes Payable (Details 1)

Notes Payable (Details 1)	Mar. 31, 2023 USD ($)
Unearned Discount [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Year ending June 30, 2023 (Remaining 3 months)	$ 400,362
2024	1,023,145
2025	111,212
Total	1,534,719
Financing Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Year ending June 30, 2023 (Remaining 3 months)	42,555
2024	108,751
2025	11,820
Total	163,126
Loan Accretion Premium [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Year ending June 30, 2023 (Remaining 3 months)	92,727
2024	236,970
2025	25,758
Total	$ 355,455

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Debt Instrument [Line Items]
Interest rate			8%
Fair value of warrants			$ 1,400,000
Fair value of embedded conversion option			2,200,000
Unearned discount	$ 400,000		3,700,000	$ 3,100,000
Direct financing cost			390,000
Unamortized premium recognized	850,000		850,000
Interest expense	1,100,000	$ 919,000	3,200,000	1,200,000
Interest payment	547,000		$ 1,500,000
Amortization of financing costs	43,000	43,000		57,000
Accretion of loan premium	$ 329,000	71,000		94,000
Notes payable		11,600,000		11,600,000
Unamortized direct costs		333,000		333,000
Unamortized accreted premium		$ 94,000		$ 94,000
Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate			7%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 4,537,206	$ 382,561
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	4,537,206	382,561
Derivative Liability Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	1,956,781	194,531
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	1,956,781	194,531	$ 1,023,294
Derivative Liability Conversion Option On Convertible Debenture [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	2,580,425	188,030
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 2,580,425	$ 188,030	$ 1,477,880

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 1) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	$ 382,561
Balance at ending	4,537,206
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	382,561
Balance at ending	4,537,206
Derivative Liability Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	194,531
Balance at ending	1,956,781
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	194,531
Additions to level 3 liabilities		1,456,512
Change in in fair value of level 3 liability	1,762,250	(433,218)
Transfer in and/or out of Level 3
Balance at ending	1,956,781	1,023,294
Derivative Liability Conversion Option On Convertible Debenture [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	188,030
Balance at ending	2,580,425
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	188,030
Additions to level 3 liabilities		2,213,466
Change in in fair value of level 3 liability	2,392,395	(735,586)
Transfer in and/or out of Level 3
Balance at ending	$ 2,580,425	$ 1,477,880

Fair Value Measurements (Deta_3

Fair Value Measurements (Details 2) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 43,797,645	$ 18,641,716
US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	18,177,285
U S Treasury Bill Securities 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	12,521,448
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	43,797,645	18,641,716
Fair Value, Inputs, Level 1 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	18,177,285
Fair Value, Inputs, Level 1 [Member] | U S Treasury Bill Securities 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	12,521,448
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | U S Treasury Bill Securities 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | U S Treasury Bill Securities 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	13,098,912	18,641,716
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	13,098,912	18,641,716
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total

Fair Value Measurements (Deta_4

Fair Value Measurements (Details Narrative) - $ / shares	1 Months Ended	9 Months Ended
	Nov. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Term		5 years	5 years
Risk Free Interest Rate		3.61%	1.60%
Volatility Rate		79.52%	75.12%
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 6.44	$ 8.08
Exercise Price	$ 5.82	$ 5.82
Term	5 years	3 years 8 months 12 days
Risk Free Interest Rate	1.14%	3.70%
Volatility Rate	74.40%	83.70%
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 6.44	$ 6.98
Exercise Price	$ 6.98
Term	3 years	1 year 8 months 12 days
Risk Free Interest Rate	0.81%	4.35%
Volatility Rate	76.85%	76.24%

Equity Transactions (Details)

Equity Transactions (Details)	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Offsetting Assets [Line Items]
Options outstanding at ending	3,443,997
Options Exercisable	1,135,948
Stock Options [Member]
Offsetting Assets [Line Items]
Options outstanding at beginning	3,398,764
Weighted average exercise price, Options outstanding at beginning | $ / shares	$ 7.42
Weighted Average Remaining Contractual Term, Options outstanding at beginning	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding at beginning of period | $
Options Granted	205,000
Weighted Average Exercise Price, Options Granted | $ / shares	$ 6.08
Weighted Average Remaining Contractual Term, Granted	5 years 2 months 12 days
Aggregate Intrinsic Value, Options Granted | $	$ 347,350
Options Expired	(10,000)
Weighted Average Exercise Price, Options Expired | $ / shares	$ 28.69
Aggregate Intrinsic Value, Options Expired | $
Options Canceled	(49,667)
Weighted Average Exercise Price, Options Canceled | $ / shares	$ 7.74
Aggregate Intrinsic Value, Options Canceled | $
Options Exercised	(100,100)
Weighted Average Exercise Price, Options Exercised | $ / shares	$ 7.79
Aggregate Intrinsic Value, Options Exercised | $
Options outstanding at ending	3,443,997
Weighted Average Exercise Price, Options outstanding at ending | $ / shares	$ 7.29
Weighted Remaining Average Contractual Term, Ending Balance	6 years
Aggregate Intrinsic Value, Outstanding at end of period | $	$ 6,474,701
Options Exercisable	1,135,948
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 8.60
Weighted Average Remaining Contractual Term, Options Exercisable	5 years 9 months 18 days
Aggregate Intrinsic Value, Options Exercisable | $	$ 1,427,537

Equity Transactions (Details 1)

Equity Transactions (Details 1)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Equity [Abstract]
Expected life of options (In years)	5 years	5 years
Expected volatility	79.52%	75.12%
Risk free interest rate	3.61%	1.60%
Dividend Yield	0%	0%

Equity Transactions (Details 2)

Equity Transactions (Details 2)	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Offsetting Assets [Line Items]
Outstanding	3,443,997
Exercisable	1,135,948
Stock Option 1 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 1.69
Outstanding	124,520
Weighted Average Contractual Life	4 years 3 months 18 days
Exercisable
Stock Option 2 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 1.81
Outstanding	10,000
Weighted Average Contractual Life	4 years 2 months 12 days
Exercisable
Stock Option 3 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 1.98
Outstanding	72,000
Weighted Average Contractual Life	4 years 2 months 12 days
Exercisable	2,000
Stock Option 4 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 2.74
Outstanding	124,167
Weighted Average Contractual Life	8 years 10 months 24 days
Exercisable	28,972
Stock Option 5 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 2.80
Outstanding	5,600
Weighted Average Contractual Life	1 year 10 months 24 days
Exercisable	5,600
Stock Option 6 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 3.20
Outstanding	248,167
Weighted Average Contractual Life	8 years 10 months 24 days
Exercisable	73,634
Stock Option 7 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 3.24
Outstanding	25,000
Weighted Average Contractual Life	8 years 10 months 24 days
Exercisable	5,417
Stock Option 8 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 3.75
Outstanding	4,800
Weighted Average Contractual Life	10 months 24 days
Exercisable	4,800
Stock Option 9 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 5.04
Outstanding	755,000
Weighted Average Contractual Life	4 years 4 months 24 days
Exercisable	188,750
Stock Option 10 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 5.21
Outstanding	10,000
Weighted Average Contractual Life	9 years 8 months 12 days
Exercisable
Stock Option 11 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 6.12
Outstanding	195,000
Weighted Average Contractual Life	4 years 8 months 12 days
Exercisable	48,750
Stock Option 12 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 6.25
Outstanding	1,600
Weighted Average Contractual Life	7 months 6 days
Exercisable	1,600
Stock Option 13 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 7.50
Outstanding	800
Weighted Average Contractual Life	1 year 7 months 6 days
Exercisable	800
Stock Option 14 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 7.74
Outstanding	1,241,668
Weighted Average Contractual Life	8 months 12 days
Exercisable	447,000
Stock Option 15 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 8.75
Outstanding	1,600
Weighted Average Contractual Life	9 months 18 days
Exercisable	1,600
Stock Option 16 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 9.54
Outstanding	800
Weighted Average Contractual Life	2 years 7 months 6 days
Exercisable	800
Stock Option 17 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 9.90
Outstanding	800
Weighted Average Contractual Life	2 years 7 months 6 days
Exercisable	800
Stock Option 18 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 13.91
Outstanding	618,475
Weighted Average Contractual Life	2 years 9 months 18 days
Exercisable	321,425
Stock Option 19 [Member]
Offsetting Assets [Line Items]
Exercise Price | $ / shares	$ 42.09
Outstanding	4,000
Weighted Average Contractual Life	2 years 10 months 24 days
Exercisable	4,000

Equity Transactions (Details 3)

Equity Transactions (Details 3) - Warrant [Member]	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant Outstanding, at the beginning of the period | shares	510,372
Weighted Average Exercise Price, at the beginning of the period | $ / shares	$ 6.17
Weighted Average Remaining Life, at the beginning of the period	3 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding at beginning of period | $
Warrant Outstanding, granted | shares	7,272,728
Weighted Average Exercise Price, granted | $ / shares	$ 1.82
Weighted Average Remaining Life, Granted	4 years 10 months 24 days
Warrant Expired | shares	(4,815)
Weighted Average Exercise Price, Expired | $ / shares	$ 75
Warrant Exercised | shares	(8,000)
Weighted Average Exercise Price, Exercised | $ / shares	$ 2.25
Warrant Outstanding, at the end of period | shares	7,770,285
Weighted Average Exercise Price, at the end of period | $ / shares	$ 2.06
Weighted Average Remaining Life, at the end of period	4 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding at end of period | $	$ 46,935,207

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Feb. 09, 2023

Dec. 06, 2022

Feb. 01, 2022

May 12, 2023

Feb. 16, 2023

Nov. 30, 2022

Nov. 23, 2022

Oct. 31, 2022

Jun. 21, 2022

Sep. 24, 2021

Aug. 20, 2021

Apr. 04, 2023

Mar. 31, 2023

Mar. 31, 2022

Mar. 31, 2023

Mar. 31, 2022

Class of Stock [Line Items]

Stock-based compensation expense

$ 3,480,425

$ 4,004,718

Total compensation cost

$ 1,744,192

Stock Option And Warrants [Member]

Class of Stock [Line Items]

Shares issued for stock option

800

3,590

21,882

Stock option to purchase

800

8,000

99,300

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.80

$ 2.25

$ 7.64

$ 7.64

Restricted Stock Units (RSUs) [Member]

Class of Stock [Line Items]

Stock-based compensation expense

584,424

$ 384,456

$ 17,536

$ 52,610

Shares issued over the vesting period

39,089

72,612

58,759

Awarded Vested rights, percentage

25%

Shares issued to employees

22,800

Restricted Stock Units (RSUs) [Member] | Four Directors [Member]

Class of Stock [Line Items]

Stock-based compensation expense

952,492

Restricted Stock Units (RSUs) [Member] | Three Directors [Member]

Class of Stock [Line Items]

Stock-based compensation expense

$ 791,700

Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member]

Class of Stock [Line Items]

Rsu granted

58,759

Rsu granted, grant date fair value

$ 7.74

Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member] | President And C E O [Member]

Class of Stock [Line Items]

Rsu granted

506,496

124,520

Rsu granted, grant date fair value

$ 6.12

$ 1.69

Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member] | Four Directors [Member]

Class of Stock [Line Items]

Rsu granted

155,636

Rsu granted, grant date fair value

$ 6.12

Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member] | Three Directors [Member]

Class of Stock [Line Items]

Rsu granted

195,000

Rsu granted, grant date fair value

$ 6.12

Common Class A [Member]

Class of Stock [Line Items]

Issuance of common stock for cash, shares

2,592,000

Share Price

$ 8

$ 8

$ 8

Issuance of common stock for cash

$ 18,500,000

Issuance costs

$ 29,000

2,200,000

Net proceeds value

$ 707,000

Common Class A [Member] | Sales Agreement [Member]

Class of Stock [Line Items]

Issuance of common stock for cash, shares

1,515,078

7,372,691

Issuance of common stock for cash

$ 9,800,000

$ 48,200,000

Issuance costs

$ 339,000

$ 1,900,000

Commissions percentage

3%

3%

Common Class A [Member] | Sales Agreement [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Issuance of common stock for cash, shares

162,767

Issuance of common stock for cash

$ 1,300,000,000

Stock Options [Member]

Class of Stock [Line Items]

Stock-based compensation expense

$ 888,998

$ 930,334

$ 3,480,425

$ 4,004,718

Options Grants

205,000

Weighted Average Exercise Price, Options Grants

$ 6.08

Equity Option [Member] | Executive [Member]

Class of Stock [Line Items]

Options Grants

1,365,835

Weighted Average Contractual Term, Granted (in Years)

5 years

Weighted Average Exercise Price, Options Grants

$ 7.74

Equity Option [Member] | New Employee [Member]

Class of Stock [Line Items]

Options Grants

10,000

Weighted Average Contractual Term, Granted (in Years)

48 months

5 years

Weighted Average Exercise Price, Options Grants

$ 5.21

$ 3.20

Equity Option [Member] | New Employee [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Stock option to purchase

124,167

Equity Option [Member] | New Employee [Member] | Minimum [Member]

Class of Stock [Line Items]

Awarded Vested rights, percentage

20%

Equity Option [Member] | New Employee [Member] | Minimum [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Awarded Vested rights, percentage

20%

Equity Option [Member] | New Employee [Member] | Maximum [Member]

Class of Stock [Line Items]

Awarded Vested rights, percentage

80%

Equity Option [Member] | New Employee [Member] | Maximum [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Awarded Vested rights, percentage

80%

Leases (Details)

Leases (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Leases
Operating lease, right-of-use asset, net	$ 90,549	$ 118,254
Current portion of operating lease liabilities	43,314	38,884
Operating lease liabilities, net of current portion	54,465	87,414
Total operating lease liabilities	$ 97,779	$ 126,298

Leases (Details 1)

Leases (Details 1) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Leases
Year ending June 30, 2023 (Remaining 3 months)	$ 12,900
2024	52,156
2025	44,636
Total minimum lease payments	109,692
Less amount representing interest	11,913
Present value of future minimum lease payments	97,779	$ 126,298
Less current portion of operating lease liabilities	(43,314)	(38,884)
Operating lease liabilities, net of current portion	$ 54,465	$ 87,414

Leases (Details 2)

Leases (Details 2)	Mar. 31, 2023	Jun. 30, 2022
Leases
Weighted average remaining lease term (Years) Operating leases	2 years	2 years 9 months 18 days
Weighted average discount rate Operating leases	10.75%	10.75%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating lease cost	$ 13,000	$ 23,000	$ 36,900	$ 76,500
Cash paid for amounts included in measurement of lease liabilities			$ 12,650	$ 37,700

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Employee Benefit Plan
Employee Benefit Plan	$ 16,000	$ 28,700	$ 80,100	$ 75,100

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Common Class A [Member] - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	May 12, 2023	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Subsequent Event [Line Items]
Issuance of common stock for cash, shares				2,592,000
Proceeds from issuance of common stock				$ 18,500,000
Sales Agreement [Member]
Subsequent Event [Line Items]
Issuance of common stock for cash, shares		1,515,078	7,372,691
Proceeds from issuance of common stock		$ 9,800,000	$ 48,200,000
Subsequent Event [Member] | Sales Agreement [Member]
Subsequent Event [Line Items]
Issuance of common stock for cash, shares	162,767
Proceeds from issuance of common stock	$ 1,300,000,000
Issuance costs	$ 40,000